Dornase Alfa as a Potential Treatment Option for SARS-CoV-2: In Vitro Insights
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The potential use of dornase alfa (DA) for managing severe acute respiratory syndrome coronavirus 2 infection has been a topic of frequent discussion; however, its underlying mechanism of effectiveness remains insufficiently explored. By shedding light on the mechanisms involved, this research endeavors to contribute to the broader understanding of DA's suitability as a potential treatment option for SARS-CoV-2 infection. In this study, the effects of DA on SARS-CoV-2 were investigated to determine the change in the level of viral cytotoxicity, viral RNA fragmentation, spike blockage, in vitro Th1/Th2 cytokine ratio of viral peptide stimulated lymphocytes and netosis Neutrophil extracellular traps formation. The analysis demonstrated that DA decreased the viral cytotoxicity at 30U (p
Fields of Study & Subjects
SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
SARS-CoV-2 detection and testing
Publication details
- Journal / source
- Fabad Journal of Pharmaceutical Sciences
- Volume
- 51
- Issue
- 1
- Pages
- 175–188
- Publication date
- 31 March 2026
- Language
- TR